Bicara Therapeutics BCAX
$8.44 −$0.68 (-7.46%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.44 0.00%
Open$8.83
Prev close$9.12
Day range$8.43 – $9.14
Volume814.5K
Market cap$560.31M
P/E (TTM)–
Dividend yield–
BCAX Stock News
Headlines matching Bicara Therapeutics or the BCAX ticker, most recent first.
- JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30
- Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $45 Negative
- Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
- Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
- Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX) Positive
- Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $37
- Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL)
- BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $34
- BTIG Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $39 Positive
- Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX)
- Analysts Have Conflicting Sentiments on These NA Companies: Bending Spoons (BSP), EToro (ETOR) and Bicara Therapeutics Inc. (BCAX)
- Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Bicara Therapeutics Inc. (BCAX) and Concentra Group Holdings Parent, Inc. (CON)
- BTIG Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $28
- Bicara Therapeutics Inc. (BCAX) Gets a Hold From Wells Fargo
- BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
No comments yet — be the first to weigh in on BCAX.
Sign in to join the discussion.